Presentation
13 March 2024 Paired-agent imaging for measuring drug-target interactions in vivo
Author Affiliations +
Abstract
The failure rate of drug development is high, especially in Phase III clinical trials after significant time and monetary investment. This can be observed in oncology trials, where drug failure rates are much higher than non-oncological trials due to inadequate improvement in overall survival. To address this problem, we propose the use of fluorescence paired-agent imaging (PAI) to monitor drug-receptor interactions in vivo in individual patients. Therapeutic agents can be conjugated to fluorophores used for measuring target-specific interactions. Our preclinical progress will be discussed for both oncology and non-oncology applications with promising translation to clinical applications in the future.
Conference Presentation
© (2024) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Kimberley S. Samkoe, Jonathan T. Elliott, Lei Wang, Summer Gibbs, and Kenneth M. Tichauer "Paired-agent imaging for measuring drug-target interactions in vivo", Proc. SPIE PC12821, Visualizing and Quantifying Drug Distribution in Tissue VIII, PC1282102 (13 March 2024); https://doi.org/10.1117/12.3008552
Advertisement
Advertisement
KEYWORDS
In vivo imaging

Proteins

Animal model studies

Cell death

Molecules

Oncology

Therapeutics

RELATED CONTENT

eEF2K: a potential cure for cancer
Proceedings of SPIE (January 08 2024)
Optical imaging of RNAi-mediated silencing of cancer
Proceedings of SPIE (February 13 2008)
The scientific basis of PDT
Proceedings of SPIE (December 12 2003)

Back to Top